ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 14, 2015
Altria Receives Augmented Stake in AB-Inbev-SABMiller Combination
Shares of newsletter portfolio holding Altria continue to rise on news of the mega deal between AB-InBev and SABMiller.
Oct 14, 2015
Video: Are Economic Moats Priced Into Stock Prices? -- You Bet They Are
President of Equity Research Brian Nelson debunks the myth that economic moats are not included in stock prices. Length: ~8 minutes.
Oct 12, 2015
EMC Will Go Private in Giant Tech Deal
Privately-held Dell has announced the acquisition of EMC in the largest “tech-only” deal in history.
Oct 11, 2015
Dividend Increases for the Week Ending October 9
Let's take a look at companies raising their dividends this week.
Oct 9, 2015
Asset Managers: Capital Retention In the Name of Capital Preservation
For asset managers, the focus has shifted to capital preservation more so than ever before following the missteps of the Financial Crisis.
Oct 9, 2015
Alcoa Disappoints in Third Quarter, China Weakness Prevalent
Performance at the aluminum giant speaks of more difficult times to come.
Oct 7, 2015
US Auto Sales Continue Breakneck Pace in September
US auto sales experienced significant growth in the month of September on its way to the best seasonally-adjusted annual rate in a given month since July 2005.
Oct 7, 2015
Yum! Brands Blows Up
What to do now?
Oct 6, 2015
Transaction Alerts: Moving Closer to Market Neutral on Energy
The absence of energy exposure in the Best Ideas Newsletter portfolio for much of the slide in the price of crude oil has been a tremendous source of upside. The elimination of several profitable positions in the Dividend Growth Newsletter portfolio several months ago has added to significant outperformance there. But now…we’re inching back into energy, if ever so slightly and on a highly diversified basis.
Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.